Toll free

18002022232

Volume 2
issue 4

Insights into global breakthroughs in cell-based therapies

IN-VIVO CAR ENGINEERING | KRAS G12D DEGRADER TRIAL | SMM EARLY TREATMENT APPROVAL | AI NANO LIQUID BIOPSY

Previous issue
Next issue
Programmable In-Vivo Hematopoietic Stem Cell (HSC) Engineering via Virus-Like Particles Produces Lineage-Specific Multiplexed CAR Effector Cells for Robust Tumour Control

This study demonstrates a novel in-vivo molecular CAR therapy in which hematopoietic stem cells (HSCs) are genetically engineered directly in the body using a high-capacity virus-like particle (VLP) platform to generate lineage-restricted HER2 CAR macrophages, CAR-NK cells, and CAR-T cells. By targeting CD46-expressing primitive HSCs and enabling stable transgene integration, a single in-vivo intervention produced durable, multi-lineage CAR immune cells for at least five months, with evidence of long-term HSC engraftment shown by secondary transplantation. Functionally, these HSC-derived CAR-M, NK, and T cells cooperated to infiltrate tumors, remodel the tumor microenvironment, and suppress solid tumor growth in immunocompetent mouse models.

Clinical Implications
  • Durable efficacy: Self-renewing HSCs act as a long-term reservoir of CAR immune cells, supporting sustained anti-tumor activity without repeated dosing.
  • Improved solid tumor control: Combined CAR-M, CAR-NK, and CAR-T activity addresses poor trafficking, immunosuppressive TME, and antigen heterogeneity.
  • Reduced manufacturing burden: Eliminates complex ex-vivo cell production and may reduce or even avoid the need for lymphodepletion.
  • Broader patient access: An in-vivo, off-the-shelf-like approach could significantly lower cost and expand eligibility.
Why It Matters
  • Durable multi-lineage immunity: HSC-derived CAR-M, CAR-NK, and CAR-T cells co-operate for long-term solid tumor control.
  • Overcomes major solid tumor barriers: Addresses poor trafficking, immunosuppressive TME, and limited persistence.
  • Simplified and scalable therapy: In-vivo engineering bypasses patient-specific manufacturing, lowering cost and expanding access.
  • Potential paradigm shift: Converts the patient’s hematopoietic system into a renewable source of anti-tumor immunity.

Reference: Zhou Y et al., J. Immunother Cancer 2023;11:e005142

Phase 1/2 Study of ARV-806, A Proteolysis Targeting Chimera (PROTAC) KRAS G12D Degrader, in KRAS G12D Mutated Advanced Solid Tumours

ARV-806 is a first-in-class proteolysis targeting chimera (PROTAC) designed to selectively degrade KRAS G12D, the most prevalent KRAS mutation in cancer and a major unmet medical need in pancreatic, colorectal, and lung cancers. Unlike conventional KRAS inhibitors, ARV-806 induces proteasomal degradation of both GDP- and GTP-bound KRAS G12D, robustly reducing mutant KRAS levels and inhibiting downstream signaling. In preclinical models, ARV-806 demonstrated strong tumor regression in xenograft and PDX models supporting further clinical evaluation. Early results from a phase 1/2 trial (NCT07023731) are ongoing, evaluating pharmacokinetics, safety, and preliminary efficacy in patients with KRAS G12D-mutant advanced solid tumors, with a focus on pancreatic ductal adenocarcinoma (PDAC).

Clinical Implications
  • Addresses a critical unmet need: Currently, there are no approved therapies for KRAS G12D-mutant cancers, particularly PDAC.
  • Mechanistic advantage: Degradation (not inhibition) of KRAS G12D overcomes limitations of target occupancy and signaling rebound.
  • Broad applicability: Potential utility across pancreatic, colorectal, and lung cancers harboring KRAS G12D.
  • Favorable dosing paradigm: Low-dose IV, intermittent schedules with strong preclinical efficacy.
Why This Matters
  • Novel breakthrough strategy: ARV-806 uses targeted protein degradation to eliminate KRAS G12D, overcoming a major limitation of traditional KRAS inhibitors.
  • High clinical relevance: It addresses a critical unmet need in KRAS G12D-mutant cancers, particularly pancreatic ductal adenocarcinoma.
  • Strong translational potential: Compelling preclinical efficacy and a rational phase 1/2 design position ARV-806 as a potentially first-in-class therapy if clinical benefit is confirmed.

Reference: Mucins-Govil T et al., Clin Oncol 2024;42(3):TPS792

First Approved Treatment for Smouldering Multiple Myeloma on January 27, 2026

On January 27, 2026, daratumumab and hyaluronidase (Darzalex Faspro) became the first FDA-approved therapy for high-risk smouldering multiple myeloma (SMM). SMM has historically been managed with observation alone despite a substantial risk of progression to active multiple myeloma. This approval marks a major shift toward early therapeutic intervention. Daratumumab, an anti-CD38 monoclonal antibody, induces immune-mediated death of malignant plasma cells, while hyaluronidase enables subcutaneous delivery by enhancing tissue permeability, improving convenience and feasibility for long-term treatment in asymptomatic patients.

Clinical Implications
  • Practice-changing approval: Introduces active treatment for high-risk SMM, replacing watchful waiting in a defined patient population.
  • Disease interception strategy: Early targeting of CD38-positive clonal plasma cells may delay or prevent progression to symptomatic multiple myeloma.
  • Patient-friendly regimen: Subcutaneous administration supports outpatient use and better adherence in asymptomatic individuals.
Why It Matters
  • First-in-class milestone: DARZALEX FASPRO® is the first approved therapy for high-risk smouldering multiple myeloma.
  • Shift to early intervention: Validates disease-interception as a new paradigm in multiple myeloma management.
  • Clinical impact: Offers a well-tolerated, targeted option that may meaningfully delay progression to active disease.

Reference: AACR, FDA Approvals in Oncology: October–December 2025

Intelligent Nano-Fingerprinting: An Efficient and Precise Approach for Liquid Biopsy

A group of scientists at the Zhejiang University, China has developed a novel technology for disease detection using liquid biopsy. This work introduces an intelligent nano-fingerprinting strategy for liquid biopsy that leverages single-molecule nano-pore technology combined with AI-based classification to analyse complex plasma matrices holistically. Instead of targeting predefined biomarkers, the approach captures global molecular fingerprints of blood in a label-free, amplification-free, and minimal-processing manner. Using only microlitre-scale volumes and simple dilution, nano-pore signals reflecting the intrinsic molecular heterogeneity of plasma are generated and accurately classified by intelligent algorithms, enabling efficient and potentially scalable disease detection.

Clinical Implications
  • Holistic diagnostics: Moves beyond single or multi-biomarker assays to capture integrated molecular changes that better reflect systemic disease states.
  • Simplified workflow: Eliminates complex extraction, enrichment, and multi-omics preprocessing, reducing variability, cost, and sample requirements.
  • Scalable screening potential: Label-free, low-volume, and rapid testing makes it suitable for large-scale population screening and longitudinal monitoring.
  • Adjunct to precision medicine: Can complement existing diagnostics to improve early detection, stratification, and understanding of disease mechanisms.
Why It Matters
  • Addresses a core limitation of liquid biopsy: Overcomes the specificity and information-loss issues inherent to single-biomarker and heavily processed multi-omics approaches.
  • Captures system-level biology: Reflects the true molecular complexity of blood as an integrated network rather than isolated components.
  • Enables early and accessible detection: The simplicity and efficiency of nanopore-AI profiling lower barriers to clinical adoption, supporting earlier intervention and better allocation of healthcare resources.

Reference: Yuxin Yang et. al., 2026, physics.bio-ph doi.org/10.48550/arXiv.2601.11947

At SunAct, we remain dedicated to tracking and sharing global advances that continue to redefine the landscape of cellular therapy and oncology. Stay tuned for our next edition as we uncover more breakthroughs and emerging trends shaping the future of cancer research.

Disclaimer: This newsletter is intended for healthcare professionals and researchers. Information is for educational purposes only.

Download PDF
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male